New and old therapeutics for oral ulcerations

Archives of Dermatology

Volumn 143, Issue 4, 2007, Pages 519-523

  Bruce, Alison ^a   Rogers III, Roy S ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PENTOXIFYLLINE; PLACEBO; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

APHTHOUS STOMATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HUMAN; MOUTH ULCER; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; SKIN EXAMINATION; ULCER HEALING; UNSPECIFIED SIDE EFFECT;

HUMANS; LICHEN PLANUS, ORAL; PENTOXIFYLLINE; RECURRENCE; STOMATITIS, APHTHOUS; TACROLIMUS;

EID: 34247375860     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.4.519     Document Type: Editorial

References (52)

1. Thornhill MH, Baccaglini L, Theaker E, Pemberton MN. A randomized, doubleblind, placebo-controlled trial of pentoxifylline for the treatment of recurrent aphthous stomatitis. Arch Dermatol. 2007;143:463-470.
2. Torti DC, Jorizzo JL, McCarty MA. Oral lichen planus: a case series with emphasis on therapy. Arch Dermatol. 2007;143:511-515.
3. Passeron T, Lacour J-P, Fontas E, Ortonne J-P. Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood. Arch Dermatol. 2007; 143:472-476.
4. Rogers RS III. Recurrent aphthous stomatitis: clinical characteristics and evidence for an immunopathogenesis. J Invest Dermatol. 1977;69:499-509.
5. Hutton KP, Rogers RS III. Recurrent aphthous stomatitis. Dermatol Clin. 1987; 5:761-768.
6. Rogers RS III. Recurrent aphthous stomatitis: clinical characteristics and associated systemic disorders. Semin Cutan Med Surg. 1997;16:278-283.
7. Bouquot JE, Gorlin RJ. Leukoplakia, lichen planus, and other oral keratoses in 23,616 white Americans over the age of 35 years. Oral Surg Oral Med Oral Pathol. 1986;61:373-381.
8. Scully C, Beyli M, Ferreiro MC, et al. Update on oral lichen planus: etiopathogenesis and management. Crit Rev Oral Biol Med. 1998;9:86-122.
9. Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol. 2002;46:207-214.
10. Bruce AJ, Rogers RS III. Acute oral ulcers. Dermatol Clin. 2003;21:1-15.
11. Zunt SL. Recurrent aphthous stomatitis. Dermatol Clin. 2003;21:33-39.
12. Lo Muzio L, della Valle A, Mignogna MD, et al. The treatment of oral aphthous ulceration or erosive lichen planus with topical clobetasol propionate in three preparations: a clinical and pilot study on 54 patients. J Oral Pathol Med. 2001; 30:611-617.
13. Ship JA. Recurrent aphthous stomatitis: an update. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;81:141-147.
14. Rogers RS III, Sams WM Jr, Shorter RG. Lymphocytotoxicity in recurrent aphthous stomatitis: lymphocytotoxicity for oral epithelial cells in recurrent aphthous stomatitis and Bechet syndrome. Arch Dermatol. 1974;109:361-363.
15. Jurge S, Kuffer R, Scully C, Porter SR. Mucosal disease series: number VI: recurrent aphthous stomatitis. Oral Dis. 2006;12:1-21.
16. Natah SS, Hayrinen-Immonen R, Hietanen J, Malmstrom M, Konttinen YT. Immunolocalization of tumor necrosis factor-α expressing cells in recurrent aphthous ulcer lesions (RAU). J Oral Pathol Med. 2000;29:19-25.
17. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor production by stimulated human monocytes. J Exp Med. 1991;173:699-703.
18. Revuz J, Guillaume JC, Janier M, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol. 1990;126:923-927.
19. Paterson DL, Georghiou PR, Allworth AM, Kemp RJ. Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. Clin Infect Dis. 1995;20:250-254.
20. de Wazieres B, Gil H, Magy N, et al. Treatment of recurrent ulceration with low doses of thalidomide: pilot study in 17 patients [in French]. Rev Med Interne. 1999;20:567-570.
21. De Wazieres B, Gil H, Vuitton DA, Dupond JL. Treatment of recurrent oro-genital ulceration with low doses of thalidomide [letter]. Clin Exp Rheumatol. 1999; 17:393.
22. Pizarro A, Navarro A, Fonseca E, Vidaurrazaga C, Herranz P. Treatment of recurrent aphthous stomatitis with pentoxifylline. Br J Dermatol. 1995;133:659-660.
23. Pizarro A, Herranz P, Navarro A, Casado M. Recurrent aphthous stomatitis: treatment with pentoxifylline. Acta Derm Venereol. 1996;76:79-80.
24. Wahba-Yahav AV. Pentoxifylline in intractable recurrent aphthous stomatitis: an open trial. J Am Acad Dermatol. 1995;33:680-682.
25. Pizarro A, Herranz P, de Lucas R, Borbujo J, Casado M. Pentoxifylline in recurrent aphthous stomatitis [commentary]. J Am Acad Dermatol. 1997;36(2, pt 1):284.
26. Chandrasekhar J, Liem AA, Cox NH, Paterson AW. Oxypentifylline in the management of recurrent aphthous oral ulcers: an open clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;87:564-567.
27. Letsinger JA, McCarty MA, Jorizzo JL. Complex aphthosis: a large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide. J Am Acad Dermatol. 2005;52:500-508.
28. Rogers RS III. Complex aphthosis. Adv Exp Med Biol. 2003;528:311-316.
29. Scully C, Gorsky M, Lozada-Nur F. The diagnosis and management of recurrent aphthous stomatitis: a consensus approach. J Am Dent Assoc. 2003;134:200-207.
30. Convit J, Goihman-Yahr M, Rondon-Lugo AJ. Effectiveness of dapsone in Behcet's disease. Br J Dermatol. 1984;111:629-630.
31. Handfield-Jones S, Allen BR, Littlewood SM. Dapsone use with oral-genital ulcers [letter]. Br J Dermatol. 1985;113:501.
32. Rogers RS III, Eisen D. Erosive oral lichen planus with genital lesions: the vulvovaginal-gingival syndrome and the peno-gingival syndrome. Dermatol Clin. 2003; 21:91-98, vi-vii.
33. Pelisse M. The vulvo-vaginal-gingival syndrome: a new form of erosive lichen planus. Int J Dermatol. 1989;28:381-384.
34. Harewood GC, Murray JA, Cameron AJ. Esophageal lichen planus: the Mayo Clinic experience. Dis Esophagus. 1999;12:309-311.
35. Abraham SC, Ravich WJ, Anhalt GJ, Yardley JH, Wu TT. Esophageal lichen planus: case report and review of the literature. Am J Surg Pathol. 2000;24:1678-1682.
36. Byrd JA, Davis MD, Bruce AJ, Drage LA, Rogers RS III. Response of oral lichen planus to topical tacrolimus in 37 patients. Arch Dermatol. 2004;140:1508-1512.
37. Byrd JA, Davis MD, Rogers RS III. Recalcitrant symptomatic vulvar lichen planus: response to topical tacrolimus. Arch Dermatol. 2004;140:715-720.
38. Ingafou M, Leao JC, Porter SR, Scully C. Oral lichen planus: a retrospective study of 690 British patients. Oral Dis. 2006;12:463-468.
39. Bruce AJ, Rogers RS III. Oral lichen planus. In: Lebwohl MG, ed. Treatment of Skin Disease: Comprehensive Therapeutic Strategies. 2nd ed. Philadelphia, Pa: Mosby Elsevier; 2006:444-446.
40. Bruce AJ. Lichen planus. http://pier.acponline.org/physicians/diseases/ d169. Accessed December 2006.
41. Zakrzewska JM, Chan ES, Thornhill MH. A systematic review of placebocontrolled randomized clinical trials of treatments used in oral lichen planus. Br J Dermatol. 2005;153:336-341.
42. Chan ES, Thornhill M, Zakrzewska J. Interventions for treating oral lichen planus. Cochrane Database Syst Rev. 2000;(2):CD001168.
43. Al-Hashimi I, Schifter M, Lockhart P. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations: consensus of the 2006 WWOM. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006. In press.
44. Rozycki TW, Rogers RS III, Pittelkow MR, et al. Topical tacrolimus in the treatment of symptomatic oral lichen planus: a series of 13 patients. J Am Acad Dermatol. 2002;46:27-34.
45. Morrison L, Kratochvil FJ III, Gorman A. An open trial of topical tacrolimus for erosive oral lichen planus. J Am Acad Dermatol. 2002;47:617-620.
46. Vente C, Reich K, Rupprecht R, Neumann C. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol. 1999;140:338-342.
47. Olivier V, Lacour JP, Mousnier A, et al. Treatment of chronic erosive oral lichen planus with low concentrations of topical tacrolimus: an open prospective study. Arch Dermatol. 2002;138:1335-1338.
48. Wooltorton E. Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): cancer concerns. CMAJ. 2005;172:1179-1180.
49. Bergdahl J, Ostman PO, Anneroth G, Perris H, Skoglund A. Psychologic aspects of patients with oral lichenoid reactions. Acta Odontol Scand. 1995;53:236-241.
50. Vujevich J, Zirwas M. Treatment of severe, recalcitrant, major aphthous stomatitis with adalimumab. Cutis. 2005;76:129-132.
51. Scheinberg MA. Treatment of recurrent oral aphthous ulcers with etanercept. Clin Exp Rheumatol. 2002;20:733-734.
52. Matsuda T, Ohno S, Hirohata S, et al. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study. Drugs R D. 2003; 4:19-28.